Who is sponsoring NCT04892680?

NCT04892680 is sponsored by Omada Health, Inc..

What drugs are being tested in NCT04892680?

Interventions in NCT04892680: Online Diabetes Self-Management Education and Support (DSMES) Program.

What condition does NCT04892680 study?

NCT04892680 studies Type 2 Diabetes.

Is NCT04892680 still recruiting?

NCT04892680 is currently terminated. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT04892680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of a Digital Self-Management Program on A1C for Individuals With Type 2 Diabetes

Terminated NA Last updated 11 May 2022

What this trial tests

NA trial testing Online Diabetes Self-Management Education and Support (DSMES) Program in Type 2 Diabetes in 27 participants. Terminated before completion.

Timeline

4 March 2021

Primary endpoint
2 August 2021

2 August 2021

Quick facts

Lead sponsor	Omada Health, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	27
Start date	4 March 2021
Primary completion	2 August 2021
Estimated completion	2 August 2021
Sites	1 location across United States

Drugs / interventions tested

Online Diabetes Self-Management Education and Support (DSMES) Program

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Omada Health, Inc.

Who can join

Adults 18 to 65, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Online Diabetes Self-Management Education and Support (DSMES) Program

Trials testing the same drug.

NCT05368454 — Evaluation of a Digital Diabetes Self-Management Education and Support Program · NA · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Omada Health, Inc. trials

Trials by the same sponsor.

NCT05368454 — Evaluation of a Digital Diabetes Self-Management Education and Support Program · NA · completed
NCT03312764 — Preventing Diabetes With Digital Health and Coaching · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04892680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Omada Health, Inc.
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04892680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing